Collaborative Arrangements - Aggregate VIE Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Jun. 30, 2015	Jun. 04, 2015
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Benefit from) provision for income taxes	$ (503)	$ (1,330)	$ (24,118)	$ (31,760)
Net (income) loss attributable to noncontrolling interest	696	(1,333)	(33,207)	30,909
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:
Restricted cash and cash equivalents (VIE)	58,420		58,420		$ 78,910
Prepaid expenses and other current assets	61,012		61,012		54,736
Intangible assets	284,340		284,340		284,340
Goodwill	50,384		50,384		50,384
Other assets	10,002		10,002		6,912
Accounts payable	50,914		50,914		74,942
Other current liabilities	292,015		292,015		305,820
Deferred tax liability, net	133,270		133,270		110,439
Other liabilities	30,524		30,524		31,778
Noncontrolling interest	186,795		186,795		153,661
BioAxone Biosciences Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Contingent consideration, liability	28,800		28,800		28,000
Parion Sciences, Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Benefit from) provision for income taxes	(500)		(20,100)
Contingent consideration, liability	232,500		232,500		179,000
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:
Intangible assets						$ 255,300	$ 255,340
Goodwill							10,468
Deferred tax liability, net							$ 91,023
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Loss attributable to noncontrolling interest before provision for income taxes	2,406	1,743	6,080	3,322
(Benefit from) provision for income taxes	(510)	777	20,063	30,367
(Increase) decrease in fair value of contingent milestone and royalty payments	(1,200)	(3,853)	(59,350)	(2,780)
Net (income) loss attributable to noncontrolling interest	696	(1,333)	(33,207)	30,909
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:
Restricted cash and cash equivalents (VIE)	58,420		58,420		78,910
Prepaid expenses and other current assets	2,360		2,360		3,138
Intangible assets	284,340		284,340		284,340
Goodwill	19,391		19,391		19,391
Other assets	382		382		455
Accounts payable	1,122		1,122		676
Taxes payable	6,263		6,263		24,554
Other current liabilities	1,121		1,121		7,100
Deferred tax liability, net	133,270		133,270		110,438
Other liabilities	300		300		300
Noncontrolling interest	186,795		186,795		$ 153,661
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Increase) decrease in fair value of contingent milestone and royalty payments	(100)	628	(850)	80
Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Increase) decrease in fair value of contingent milestone and royalty payments	$ (1,100)	$ (4,481)	$ (58,500)	$ (2,860)